MoreGoodDays: Capital Raising

The leadership read

MoreGoodDays entering ANDHealth+ commits the company to a structured commercialisation gauntlet rather than a simple capital injection. Stage one funding is shared across five companies, meaning the per-company allocation is modest; the real prize is stage two, where surviving cohort members access a larger pool explicitly designed to de-risk commercialisation and position companies for institutional follow-on or enterprise customer uptake. That framing matters: ANDHealth+ is not a product-development grant but a commercial-readiness program, which means MoreGoodDays is now accountable to milestones oriented around payer access, clinical validation at scale, and enterprise customer traction, not just platform iteration. This is one of twelve capital-raising signals we have tracked across the last 90 days; however, the related signals are broadly dispersed across AI infrastructure, gaming, fintech, and industrial tooling, only EVERSION Technologies (€2.3M seed, AI-powered medtech) sits in a clearly adjacent corridor. The ANDHealth+ cohort itself is the more useful comparator set: five companies, cardiovascular to chronic pain, all facing the same structural challenge ANDHealth CEO Bronwyn Le Grice named explicitly, constrained access to growth capital for Australian digital health founders. Companies reaching this stage of structured accelerator progression in Australian digital health face consistent pressure on commercial and regulatory capability: specifically, health system navigation, payer and insurer engagement, and the clinical-evidence packaging that converts platform efficacy data into enterprise procurement conversations. The market is moving toward operators who can hold both the clinical-partnerships and the commercial-scaling mandates simultaneously, a combination that remains scarce in the local talent pool.